Skip to main content

Genocea Biosciences, Inc. (GNCA)

NASDAQ: GNCA · Delayed Price · USD
2.09 0.00 (0.00%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap119.16M
Revenue (ttm)453,000
Net Income (ttm)-35.83M
Shares Out67.97M
EPS (ttm)-0.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume126,692
Open2.09
Previous Close2.09
Day's Range2.07 - 2.16
52-Week Range1.65 - 4.05
Beta1.64
AnalystsStrong Buy
Price Target6.10 (+191.9%)
Est. Earnings DateOct 28, 2021

About GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell the...

IndustryBiotechnology
IPO DateFeb 5, 2014
CEOWilliam Clark
Employees72
Stock ExchangeNASDAQ
Ticker SymbolGNCA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for GNCA stock is "Strong Buy." The 12-month stock price forecast is 6.10, which is an increase of 191.87% from the latest price.

Price Target
$6.10
(191.87% upside)
Analyst Consensus: Strong Buy

News

Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jen...

1 week ago - GlobeNewsWire

Genocea to Present at Upcoming Scientific and Investor Conferences

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior le...

2 weeks ago - GlobeNewsWire

Do Options Traders Know Something About Genocea (GNCA) Stock We Don't?

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Genocea Provides Second Quarter 2021 Corporate Update

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues

1 month ago - GlobeNewsWire

Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter ...

2 months ago - GlobeNewsWire

Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug

Genocea Biosciences (GNCA) doses the first patient in phase I/IIa study on its investigational neoantigen-targeted T-Cell therapy, GEN-011, for solid tumors

2 months ago - Zacks Investment Research

Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy

CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dosin...

2 months ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Genocea (GNCA) Stock?

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021

Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination was 15 months

3 months ago - GlobeNewsWire

Genocea Biosciences (GNCA) Reports Q1 Loss, Misses Revenue Estimates

Genocea Biosciences (GNCA) delivered earnings and revenue surprises of 15.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Genocea Provides First Quarter 2021 Corporate Update

GEN-011 and GEN-009 immuno-oncology programs continue to advance

4 months ago - GlobeNewsWire

Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quar...

5 months ago - GlobeNewsWire

New Strong Sell Stocks for April 13th

ASC, BCEI, XOG, GNCA, and GNLN have been added to the Zacks Rank #5 (Strong Sell) List on April 13, 2021

Other symbols:ASCBCEIGNLNXOG
5 months ago - Zacks Investment Research

Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021

Pro-tumor effects detected as early as four days after Inhibigen administration

5 months ago - GlobeNewsWire

Genocea to Present at the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chi...

5 months ago - GlobeNewsWire

Genocea to Present at the H.C. Wainwright Global Life Sciences Conference

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chi...

6 months ago - GlobeNewsWire

Genocea Provides Fourth Quarter 2020 Corporate Update

GEN-011 and GEN-009 clinical trials continue to advance

7 months ago - GlobeNewsWire

Genocea to Host Fourth Quarter 2020 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quar...

7 months ago - GlobeNewsWire

Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the A...

Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigensof anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T cell...

7 months ago - GlobeNewsWire

Genocea to Participate in the B. Riley Securities' Virtual Oncology Investor Conference

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chi...

8 months ago - GlobeNewsWire

Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chi...

8 months ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Genocea (GNCA) Stock?

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action...

Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies

10 months ago - GlobeNewsWire

Genocea to Host Investor Call Highlighting New GEN-009 Clinical and Immunogenicity Data to be Presented at Virtual SI...

Call scheduled for November 9th at 8:30 a.m. EST Call scheduled for November 9th at 8:30 a.m. EST

10 months ago - GlobeNewsWire

Genocea Biosciences, Inc's (GNCA) CEO Chip Clark on Q3 2020 Results - Earnings Call Transcript

Genocea Biosciences, Inc's (GNCA) CEO Chip Clark on Q3 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha